Corporate Presentation

Penser Market, May 25, 2023

Erik Kinnman, M.D., PhD, MBA CEO

Forward-looking statement

Important notice

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation

of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

Forward looking statements

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Vivesto believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out

in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Vivesto include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Vivesto has undertaken

to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

1

Oncology focused R&D company

  • Track record of bringing a product to the market and commercial production
    • Cost effective organization

•

•

•

New focus on developing drugs from preclinical stage to clinical PoC

Deliver opportunities in existing portfolio and XR technology platform

Expand portfolio

•

•

•

Nasdaq Stockholm mid cap: vive.st

MCAP 190 MSEK

Cash 119 MSEK Q1 2023

2

Our current portfolio

3

Portfolio and technology platform activities

Small

molecules

  • Apealea launch
    • Vivesto and Elevar seek to transfer Apealea rights to a third party
    • In parallel seek a partner for China
  • Paccal vet
    • FDA pre submission conference underway
    • Clinical trial initiation planned for H2 2023
  • Docetaxel micellar
    • Clinical study completed end 2023, results 2024
  • Cantrixil

Solubilization • technologies

(XR-17™/XR-18)•

Production clinical trial material

Alternative indications investigated: bladder and hematological cancer

  • XR drug delivery platform progress

4

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Vivesto AB published this content on 25 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 May 2023 12:32:29 UTC.